AI-generated summary
The authors report a preliminary open-label case series of 10 patients with hair loss or telogen effluvium linked to COVID-19, treated with micro-needling, low-level LED therapy and growth factors. Hair density rose by 11 hairs per square centimeter after 20 weeks, a difference the authors describe as not quite statistically significant. They conclude the results are preliminary and require controlled trials to confirm them.
- Participants
- 10
- Who or what was studied
- 10 patients (6 men and 4 women) with hair loss or telogen effluvium related to COVID-19
- Limits stated in the abstract
- Small open-label case series with no control group, a short follow-up, and a difference that was not statistically significant.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The incidence of hair loss (HL) and telogen effluvium (TE) has increased due to the spread of the coronavirus disease (COVID-19) induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). New biotechnologies based on micro-needling (MND) with Low-Level LED Therapy (LLLT) and Growth Factors (GFs) used for hair re-growth (HR-G) in Androgenetic Alopecia (AGA) need to be standardized also in HL and TE related to COVID-19. This article aims to describe the preliminary clinical results obtained from an open-label case-series observational study. MND with LLLT and GFs was used in patients affected by HL and TE-related to COVID-19. In total, 10 patients (6 men were identified in stage I-III vertex according to the Norwood-Hamilton scale, and 4 women were identified in stage I-II according to the Ludwig scale) were enrolled and analyzed after screening (exclusion and inclusion criteria evaluation). HR-G assessment was analyzed through photography, physician's and patient's global assessment scale, and standardized phototrichograms during a short follow-up: T0-baseline; T1-20 weeks (wks). In the targeted area computerized trichograms showed encouraging results with a hair density increase of 11 ± 2 hairs/cm2 at T1 after 20 wks (20 wks vs. 0 wks) compared with baseline (58 ± 2 hairs/cm2 at T1 versus 47 ± 2 hairs/cm2 at baseline) with a not quite statistically significant difference in HR-G (p = 0.0690). The preliminary effectiveness of MND with LLLT and GFs use has been demonstrated in mild-to-moderate HL and TE related to COVID-19. Further controlled trials are required to confirm these preliminary results.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode, Low-level laser therapy, Androgenetic alopecia, Observational study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.